Results 1 to 10 of about 672,004 (247)

The standardization of immunohistochemical detection and interpretation of CD30 expression in lymphomas [PDF]

Zhongguo aizheng zazhi, 2023
CD30 can be expressed in a variety of lymphoma subtypes, among which classical Hodgkin lymphoma (CHL) and anaplastic large cell lymphoma (ALCL) are the most common ones.
CD-Positive Lymphoma Pathology Expert Group
doaj   +1 more source

Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse

Blood Cancer Journal, 2021
Although methotrexate (MTX) is the most widely used therapy for central nervous system (CNS) prophylaxis in patients with diffuse large B-cell lymphoma (DLBCL), the optimal regimen remains unclear.
Sabela Bobillo, Erel Joffe, David Sermer, Patrizia Mondello, Paola Ghione, Philip C. Caron, Audrey Hamilton, Paul A. Hamlin, Steven M. Horwitz, Anita Kumar, Matthew J. Matasar, Connie L. Batlevi, Alison Moskowitz, Ariela Noy, Collette N. Owens, M. Lia Palomba, David Straus, Gottfried von Keudell, Ahmet Dogan, Andrew D. Zelenetz, Venkatraman E. Seshan, Anas Younes   +21 more
doaj   +1 more source

Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre

BMC Cancer, 2023
Background Dihydropyrimidine dehydrogenase (DPD) is a key enzyme in the metabolism of fluoropyrimidines. Variations in the encoding DPYD gene are associated with severe fluoropyrimidine toxicity and up-front dose reductions are recommended.
David K. Lau, Caroline Fong, Faten Arouri, Lillian Cortez, Hannah Katifi, Reyes Gonzalez-Exposito, Muhammad Bilal Razzaq, Su Li, Aislinn Macklin-Doherty, Monica Arenas Hernandez, Michael Hubank, Charlotte Fribbens, David Watkins, Sheela Rao, Ian Chau, David Cunningham, Naureen Starling   +16 more
doaj   +1 more source

Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma

Blood Cancer Journal, 2022
Between 1998 and 2009, a total of 295 patients (median age 58, 53% females) with newly diagnosed early-stage follicular lymphoma (FL) were managed at Memorial Sloan Kettering Cancer Center.
Fushen Sha, Michelle Okwali, Anna Alperovich, Philip C. Caron, Lorenzo Falchi, Audrey Hamilton, Paul A. Hamlin, Steven M. Horwitz, Erel Joffe, Niloufer Khan, Anita Kumar, Matthew J. Matasar, Alison J. Moskowitz, Ariela Noy, Colette Owens, Lia M. Palomba, Ildefonso Rodriguez-Rivera, David Straus, Gottfried von Keudell, Andrew D. Zelenetz, Joachim Yahalom, Ahmet Dogan, Heiko Schöder, Venkatraman E. Seshan, Gilles Salles, Anas Younes, Connie L. Batlevi   +26 more
doaj   +1 more source

First experience of using Brentuximab vedotin and modified program NHL-BFM-90 in the front-line treatment of patient with anaplastic large-cell lymphoma: a case report and a review of literature [PDF]

Терапевтический архив, 2018
Nodal anaplastic ALK-negative large cell lymphoma (nALCL, ALK-) is a Т-cell lymphoma that is characterized by aggressive clinical course and low sensitivity to СНОР (cyclophosphamide, doxorubicin, vincristine, prednisolone) and other chemotherapy regimen.
N G CHERNOVA, E E ZVONKOV, D S BADMAZHAPOVA, M N SINITSYNA, L A GREBENYUK, Y V SIDOROVA, I E KOSTINA, A M KOVRIGINA, T N OBUKHOVA, A B SUDARIKOV, V G SAVCHENKO   +10 more
doaj   +1 more source

p53 directly downregulates the expression of CDC20 to exert anti-tumor activity in mantle cell lymphoma

Experimental Hematology & Oncology, 2023
Background Cell cycle dysregulation characterized by cyclin D1 overexpression is common in mantle cell lymphoma (MCL), while mitotic disorder was less studied. Cell division cycle 20 homologue (CDC20), an essential mitotic regulator, was highly expressed
Yingtong Chen, Ping Yang, Jing Wang, Shuang Gao, Shiyu Xiao, Weilong Zhang, Mingxia Zhu, Yanfang Wang, Xiaoyan Ke, Hongmei Jing   +9 more
doaj   +1 more source

How we treat mature B-cell neoplasms (indolent B-cell lymphomas)

Journal of Hematology & Oncology, 2021
Mature B cell neoplasms, previously indolent non-Hodgkin lymphomas (iNHLs), are a heterogeneous group of malignancies sharing similar disease courses and treatment paradigms. Most patients with iNHL have an excellent prognosis, and in many, treatment can
Melissa Lumish, Lorenzo Falchi, Brandon S. Imber, Michael Scordo, Gottfried von Keudell, Erel Joffe   +5 more
doaj   +1 more source

Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomes

Haematologica, 2023
Osseous involvement by diffuse large B-cell lymphoma (DLBCL-bone) is a heterogeneous disease. There is limited data regarding response assessment by positron emission tomography with fluorodeoxyglucose, which may demonstrate residual avidity despite a ...
Paola Ghione, Salma Ahsanuddin, Efrat Luttwak, Sabela Bobillo Varela, Reiko Nakajima, Laure Michaud, Kanika Gupta, Anastasia Navitski, David Straus, M. Lia Palomba, Alison Moskowitz, Ariela Noy, Paul Hamlin, Matthew Matasar, Anita Kumar, Lorenzo Falchi, Joachim Yahalom, Steven Horwitz, Andrew Zelenetz, Anas Younes, Gilles Salles, Heiko Schöder, Erel Joffe   +22 more
doaj   +1 more source

Potentiation of apoptosis in drug-resistant mantle cell lymphoma cells by MCL-1 inhibitor involves downregulation of inhibitor of apoptosis proteins

Cell Death and Disease, 2023
Bruton’s tyrosine kinase inhibitors (BTKi) and CAR T-cell therapy have demonstrated tremendous clinical benefits in mantle cell lymphoma (MCL) patients, but intrinsic or acquired resistance inevitably develops.
Yijing Li, Heng-Huan Lee, Vivian Changying Jiang, Yuxuan Che, Joseph McIntosh, Alexa Jordan, Jovanny Vargas, Tianci Zhang, Fangfang Yan, Margaret Elizabeth Simmons, Wei Wang, Lei Nie, Yixin Yao, Preetesh Jain, Michael Wang, Yang Liu   +15 more
doaj   +1 more source

Is Circulating DNA and Tumor Cells in Myeloma the Way Forward?

Hemato, 2022
Multiple myeloma (MM) is the second deadliest hematological cancer. Despite the enormous innovation on MM treatment in the last decades, still 48% of patients die within 5 years after diagnosis. MM diagnosis and therapeutic strategy mainly rely on direct
Emilie Arnault Carneiro, Filipa Barahona, Carolina Pestana, Cristina João   +3 more
doaj   +1 more source